Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by biggonadson Sep 02, 2022 2:32pm

165 Views

Post# 34938870

AGN rated an immediate buy

For reasons including Algernon’s unique position having a mere 2.4M shares OS, 3 main drug candidates all of which likely to be in Phase 2 trials in ‘23, and the positive results from the full data set of its Phase 2a study of Ifenprodil, Streetwise Reports issues an immediate buy rating from a new piece published by Streetwise Reports. https://www.streetwisereports.com/article/2022/09/01/expert-rates-pharma-co-an-immediate-buy.html

<< Previous

Bullboard Posts

Next >>

Two Venture-listed mining stocks file NI 43-101 reports